Urinary 8-Hydroxy-2'-Deoxyguanosine as a Novel Biomarker for Predicting Cardiac Events and Evaluating the Effectiveness of Carvedilol Treatment in Patients With Chronic Systolic Heart Failure

DOI DOI Web Site Web Site PubMed 20 Citations 95 References
  • Susa Takehisa
    Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine
  • Kobayashi Shigeki
    Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine
  • Tanaka Takeo
    Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine
  • Murakami Wakako
    Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine
  • Akashi Shintaro
    Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine
  • Kunitsugu Ichiro
    Department of Public Health, Yamaguchi University Graduate School of Medicine
  • Okuda Shinichi
    Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine
  • Doi Masahiro
    Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine
  • Wada Yasuaki
    Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine
  • Nao Tomoko
    Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine
  • Yamada Jutaro
    Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine
  • Ueyama Takeshi
    Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine
  • Okamura Takayuki
    Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine
  • Yano Masafumi
    Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine
  • Matsuzaki Masunori
    Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine

Bibliographic Information

Other Title
  • Low-Dose β-Blocker in Combination With Milrinone Safely Improves Cardiac Function and Eliminates Pulsus Alternans in Patients With Acute Decompensated Heart Failure
  • A low-dose β blocker in combination with milrinone safely improves cardiac function and eliminates pulsus alternans in patients with acute decompensated heart failure
  • Urinary 8-hydroxy-2′-deoxyguanosine as a novel biomarker for predicting cardiac events and evaluating the effectiveness of carvedilol treatment in patients with chronic systolic heart failure
  • Low-dose beta-blocker in combination with milrinone safely improves cardiac function and eliminates pulsus alternans in patients with acute decompensated heart failure

Search this article

Abstract

Background: The authors recently reported that urinary 8-hydroxy-2'-deoxyguanosine (U8-OHdG) derived from cardiac tissue reflects clinical status and cardiac dysfunction severity in patients with chronic heart failure (CHF). The aim of the present study was to investigate whether U8-OHdG levels can accurately predict cardiac events in CHF patients and their response to β-blocker treatment. Methods and Results: Plasma brain natriuretic peptide (BNP) and U8-OHdG levels were measured in 186 consecutive CHF patients before discharge. Patients were then prospectively followed (median follow-up, 649 days) with endpoints of cardiac death or hospitalization due to progressive heart failure. From receiver operating characteristic curve analysis, cut-offs were 12.4ng/mg creatinine (Cr) for U8-OHdG and 207pg/ml for BNP. On multivariate Cox analysis, U8-OHdG and BNP were independent predictors of cardiac events. Patients were classified into 4 groups according to U8-OHdG and BNP cut-offs. The hazard ratio for cardiac events in patients with BNP ≥207pg/ml and U8-OHdG ≥12.4ng/mg Cr was 16.2 compared with approximately 4 for patients with only 1 indicator above its respective cut-off. Furthermore, carvedilol therapy was initiated in 30 CHF patients. In responders (≥10% increase in left ventricular ejection fraction [LVEF] or ≥1 class decrease in New York Heart Association [NYHA] class), U8-OHdG levels decreased significantly along with improved NYHA class, LVEF, and BNP levels after treatment. Conclusions: U8-OHdG may be a useful biomarker for predicting cardiac events and evaluating β-blocker therapy effectiveness in CHF patients. (Circ J 2012; 76: 117-126)<br>

Journal

  • Circulation Journal

    Circulation Journal 76 (1), 117-126, 2012

    The Japanese Circulation Society

Citations (20)*help

See more

References(95)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top